A clinical trial to study the effects of Aflibercept in patients with type 2 diabetes mellitus with reduced vision.

Changes in subfoveal choroidal thickness after intravitreal Aflibercept for diabetic macular edema. - DME

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000051561

Enrollment

100

Registered

2024-01-01

Start date

2023-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Interventions

Intravitreal injection of Aflibercept

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 250u

Exclusion criteria

Exclusion criteria: Patients with proliferative diabetic retinopathy, prior intravitreal injections of anti-VEGFs or laser photocoagulation, pars plana vitrectomy, age-related macular degeneration, venous occlusion, ocular trauma, pregnancy, and ocular surgery (except cataract surgery) were excluded. Patients with less than 6 months follow-up after the 3rd injection were excluded.

Design outcomes

Primary

Measure	Time frame
Reduction in subfoveal thickness after intravitreal Aflibercept	—

Secondary

Measure	Time frame
Improvement in vision after intervention	—

Countries

Asia(except Japan)

Contacts

Public ContactPrachi Kumar

Yashoda Ghaziabad

kumarprachi@yahoo.co.in+911204181900

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026